SkinnyRx

SkinnyRx review

Introductory compounded offers. The costs, commitments and questions worth considering.

GLP1 Rank is a commercial comparison site. We may earn a commission through links. How we’re funded

Our take

SkinnyRx’s introductory pricing needs a renewal quote, and its product claims should be read alongside the FDA’s published warning letter.

Reasons to look closer

  • Injection and tablet paths distinguished
  • Published prescription-review refund boundary
  • Refill review described

Keep in mind

A first-month promotion and a regulatory warning answer different shopping questions.

The costs at a glance

Published price reference$99 first month
Compounded injection introduction
MedicationCompounded injections and tablets listed
CommitmentSubscription and bundled options
Important contextOngoing rate must be confirmed; tablet and branded paths differ.

The entry offer is not an ongoing price

SkinnyRx advertises compounded injections at $99 for the first month and compounded semaglutide tablets at $149 for the first month. Those are different formulation offers, not two prices for the same purchase. Obtain the next charge and the total for any bundled term before choosing. Our comparison uses the injection introduction and leaves the continuing cost open. Multiplying the first-month figure by twelve would imply a recurring price that has not been established.

Why the FDA letter belongs in the review

FDA issued a February 20, 2026 warning letter to Lean Rx, Inc., doing business as SkinnyRx. The letter concerns misleading promotional representations about compounded semaglutide and tirzepatide, including imagery implying the platform compounded the products and claims implying FDA evaluation. This is specific regulatory evidence about the cited marketing. It is not a clinical outcome study, a numerical quality rating or proof that every current order has the same characteristics. Build your comparison with our provider selection checklist.

What the letter does not establish

A warning letter identifies the agency’s concerns and requests a response; it does not tell a shopper whether an individual prescription is appropriate. Nor should the passage of time be treated as proof that the matter has been resolved. We have not established a closure outcome here. Ask the provider about the actual dispensing pharmacy and product, and evaluate current claims on their own wording. Keep regulatory status separate from personal treatment decisions.

Tablets need their own evidence discussion

The catalog’s compounded tablet offer should be discussed as that particular formulation. A shared ingredient name does not answer whether another product’s trial results apply. Ask the clinician what evidence supports the prescribed preparation and how follow-up will assess benefit and tolerability. Also ask how a formulation change affects the quote. The consumer task is to connect the prescription, its evidence and its price, rather than choosing between injection and tablet solely by introductory cost. For the product distinction, see branded versus compounded GLP-1s.

Cancellation changes after prescription review

The FAQ describes a refund before a provider completes prescription review, but limits refunds after fulfillment begins. It also says partially used periods and bundled subscriptions are not refundable, with promotional adjustments possible. Ask for the precise deadline for the next order and the treatment of any prepaid amount. Canceling future billing is not the same as reversing a completed medication purchase, so request confirmation of both the subscription status and any refund amount.

Plan the switch or refill with the clinician

If you are transferring from another provider, supply the current prescription and pharmacy label through the service’s secure clinical process. Ask how the new clinician reviews the existing treatment and what happens if they recommend a different plan. Do not independently change medication or dosing to use up overlapping supplies. For budgeting, request a revised quote before authorizing a changed purchase and keep the previous service’s cancellation process separate from the new enrollment.

Our assessment of SkinnyRx’s fit

SkinnyRx can be compared on its entry cost and ordering terms, but a responsible shortlist also accounts for the FDA letter and the unconfirmed ongoing rate. We would resolve the product, pharmacy, renewal price and refund boundary before paying. If those answers are incomplete, a different documented offer provides a clearer basis for comparison. A low introductory amount cannot by itself establish value, clinical suitability or the outcome a patient should expect.

Before you sign up

  • What is the price after the first month?
  • What happens to a prepaid bundle if treatment stops?
  • Which pharmacy and formulation will fulfill my prescription?

Use the answers to compare the exact offer with another provider. A service review cannot determine whether a medication is appropriate for you; that decision belongs with your clinician.

Compare the complete budget · Save your provider checklist

Research the questions behind this offer

Further reading

Other providers to compare

Compare a documented continuing price against SkinnyRx’s first-month introduction.

OrderlyMeds

Starter and ongoing plans

OrderlyMeds

$149/month

Standard compounded semaglutide plan

Introductory two-month offers have separate eligibility and upfront-payment conditions.

Compare single-month and prepaid totals before choosing an introductory offer.

Brightmeds

Monthly or prepaid compounded packages

Brightmeds

$129/month

Single-month semaglutide offer

Fall offer: $129 for one month, or $297 prepaid for a three-month pack; promotional terms can change.

Compare named pharmacy-specific plans and invoice-based purchasing.

One more option